Vertex Pharmaceuticals Stock Forecast

Stock Price Forecast

The 23 analysts with 12-month price forecasts for Vertex Pharmaceuticals stock have an average target of 505.61, with a low estimate of 408 and a high estimate of 586. The average target predicts a decrease of -0.66% from the current stock price of 508.99.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$408	$505.61	$520	$586
Change	-19.84%	-0.66%	+2.16%	+15.13%

* Price targets were last updated on Feb 20, 2025.

Analyst Ratings

The average analyst rating for Vertex Pharmaceuticals stock from 25 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Oct '24	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25
Strong Buy	10	11	12	10	10	10
Buy	8	8	8	7	6	6
Hold	9	9	9	9	9	9
Sell	0	0	0	0	0	0
Strong Sell	1	1	1	1	0	0
Total	28	29	30	27	25	25

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Brian Abrahams RBC Capital	RBC Capital	Hold Maintains $407 → $408	Hold	Maintains	$407 → $408	-19.84%	Feb 20, 2025
Whitney Ijem Canaccord Genuity	Canaccord Genuity	Strong Sell → Hold Upgrades $408 → $424	Strong Sell → Hold	Upgrades	$408 → $424	-16.70%	Feb 12, 2025
Joon Lee Truist Securities	Truist Securities	Strong Buy Maintains $460 → $520	Strong Buy	Maintains	$460 → $520	+2.16%	Feb 11, 2025
Brian Abrahams RBC Capital	RBC Capital	Hold Maintains $402 → $407	Hold	Maintains	$402 → $407	-20.04%	Feb 11, 2025
Greg Harrison Scotiabank	Scotiabank	Hold Maintains $433 → $450	Hold	Maintains	$433 → $450	-11.59%	Feb 11, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

12.19B

from 11.02B

10.64%

from 11.02B

Revenue Next Year

13.29B

from 12.19B

9.01%

from 12.19B

EPS This Year

18.38

from -2.08

EPS Next Year

20.44

from 18.38

11.21%

from 18.38

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	6.21B	7.57B	8.93B	9.87B	11.02B	12.19B	13.29B	14.48B
Revenue Growth	49.08%	22.06%	17.91%	10.51%	11.66%	10.64%	9.01%	8.93%
EPS	10.29	9.01	12.82	13.89	-2.08	18.38	20.44	23.05
EPS Growth	128.16%	-12.44%	42.29%	8.35%	-	-	11.21%	12.77%
Forward PE	-	-	-	-	-	27.69	24.90	22.08
No. Analysts	-	-	-	-	-	38	30	23

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	13.1B	14.8B	17.1B
Avg	12.2B	13.3B	14.5B
Low	11.3B	11.6B	11.6B

Revenue Growth

Revenue Growth	2025	2026	2027
High	18.7%	21.7%	28.6%
Avg	10.6%	9.0%	8.9%
Low	2.9%	-4.8%	-12.8%

EPS Forecast

EPS	2025	2026	2027
High	20.56	28.71	36.40
Avg	18.38	20.44	23.05
Low	15.62	16.23	18.70

EPS Growth

EPS Growth	2025	2026	2027
High	-	56.2%	78.1%
Avg	-	11.2%	12.8%
Low	-	-11.7%	-8.5%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.